Mutations in epigenetic regulators include TET2 mutations in 10–15%, DNMT3A and ASXL1 mutations in 5–15%, EZH2 in 3–10%, and IDH1/2 mutations in 1–2% of MPN patients. Here, EZH2 is linked to myeloproliferative neoplasm.